Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.

Ravi A MadanFatima H KarzaiMunjid Al HarthyDaniel P PetrylakJoseph W KimPhilip M ArlenInger RosnerMarc R TheoretLisa CordesMarijo BilusicCody J PeerNancy A DawsonAnna CouvillonAmy HankinMoniquea WilliamsGuin ChunHelen OwensJennifer L MarteMin-Jung LeeYusuke TomitaAkira YunoJane B TrepelSunmin LeeSeth M SteinbergJames L GulleyWilliam D FiggWilliam L Dahut

Published in: BJU international (2020)

Despite the limited number of patients in this study, preliminary data suggest that cabozantinib can be safely added to docetaxel/prednisone with possible enhanced efficacy.

Keyphrases

end stage renal disease
ejection fraction
small cell lung cancer
peritoneal dialysis
electronic health record
big data
radiation therapy
artificial intelligence
patient reported